# A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

> **NCT05600998** · NA · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05600998
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-30
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05600998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05600998, "A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05600998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*